• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

EMA: industry support increases steadily

30.05.2017/in News /by eugeneqqq

Every decent regulatory agency urges to assure pharma industry that it’s activity is guided by an effort to help, but not by an unbearable will to punish and restrict. That’s why every year EMA issues the annual report on its activities in all regulatory areas. In recently published 2016 report, among many other important points, the agency reports about its successful actions in providing advice for human medicines development and helping pharma industry with marketing authorization process.

In 2016, EMA recommended 81 medicines for marketing authorisation, including 27 new active substances. Many of approved substances were developed with EMA continuous support of scientific studies, including clinical research. In fact, more than half of the applicants received a positive opinion for their medicine had received scientific advice from EMA during the development phase of their product. Zero negative opinions were given in 2016.

EMA’s scientific advice and protocol assistance were a crucial part of drug development for big and small pharmaceutical companies. Advice and assistance were given to 405 medium and large pharmaceutical companies and 177 small and medium-sized enterprises (SME’s).

The agency considers SME’s a driver for innovation in the EU. SME’s submitted 27 applications for marketing authorisation which is the highest number for past six years. Thus, in 2016 EMA’s subdivision for such enterprises dealt with the highest number of request for direct assistance on administrative or regulatory issues related to drug development.

EMA supports orphan drug development financially, but in 2016 support was granted to R&D as well. Moreover, regulator established transparent relationships with US FDA and Japanese Pharmaceuticals and Medical Devices Agency and implicated parallel submission process for drugs intended to treat rare diseases. In fact, in 2016 EMA acted even more “orphanly”. Seven new medicines received a recommendation for marketing authorization following another special procedure – accelerated assessment. This mechanism is reserved for medicines that have the potential to address an unmet medical need in patients.

Regulator admits that despite all that achievements it hasn’t become much faster in application assessment. But in fact, this was mainly driven by pharmaceutical companies delaying an approval process themselves in order to supply the missing documents or address the agency’s comments.

Any kind of report that any organization issues about itself tend to be optimistic. But it appears, that in the case of EMA there is simply no dark side of its activity. The agency is ready to cooperate with pharmaceutical companies, thus providing better healthcare for people inside and even outside the EU.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 6 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Keytruda – a new hope for oncology. Pricy, unique and urgently needed for approval: a risky combo?
Scroll to top